Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q3 FY16 Earnings Presentation
22 slides from Alembic Pharmaceuticals's earnings presentation, January 2016
Slide 1: Investor Presentation January 2016
Alembic Pharmaceuticals Limited Investor Presentation January 2016 www.alembic-india.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 3: About Alembic
About Alembic Established in 1907 at Vadodara Demerger of pharma business from Alembic Ltd. – Alembic Pharmaceuticals Ltd. formed in 2011 Investment in Algeria JV Three API manufacturing facilities approved by USFDA One solid dosage formulation facility approved by USFDA 18 Marketing div
Slide 4: Financial Highlights Q3 FY16
Financial Highlights Q3 FY16 Net Sales up 81% to Rs 9307 mn EBITDA margins at 41% at Rs 3846 mn Net Profit up 281% to Rs 2695 mn Total R&D spend is Rs 745 mn for the quarter which is 8% of net sales. This is up by 139 % (YOY)
Slide 5: Business Highlights Q3 FY16 India Branded Formulations
Business Highlights Q3 FY16 India Branded Formulations (Rs. 2883 mn) Sikkim plant commissioned Specialty Segment grew by 22% and Acute Segment grew by 10%. Althrocin price led to lower growth Strengthening the share of specialty therapies in the overall revenue basket. Within specialty Anti Di
Slide 6: Business Highlights Q3 FY16 International Business
Business Highlights Q3 FY16 International Business (Rs. 5211 mn) Business grew by 248% in the quarter Successful Launch of Aripiprazole Generic 3 products launch in USA USA front end operational 2 ANDA approvals were received during the quarter, taking cumulative approvals at 45 including
Slide 7: Business Highlights Q3 FY16 API Business
Business Highlights Q3 FY16 API Business (Rs. 1012 mn) Business grew by 24% in the quarter 4 DMF applications were filed during the quarter, taking cumulative DMF filings at 79
Slide 8: R&D Update
R&D Update 8.6% 7.0% 6.7% 2,180 4.8% 5.1% 1,308 1,394 In INR mn 772 702 FY12 FY13 FY14 FY15 YTD DEC FY16 Total R&D spend is Rs 2180 mn for the YTD DEC FY16 which is 8.6% of net sales. Highly talented pool of 470 research scientists
Slide 9: Strong domestic market presence
Strong domestic market presence India Branded Formulation Business - Key Highlights 1.74% market share (Ranked 19th) in Indian formulations market as per IMS MAT data Ranked 17th in doctors’ prescription universe Sustained dominance in anti-infective, analgesics, cough and cold segments Robu
Slide 10: Key Therapies & Brands
Key Therapies & Brands Therapeutic Segment-wise Break-up (Q3FY16) • Launched 8 product SKUs in the domestic market in Q3FY16. % of total domestic formulation revenue Brand Name Therapeutic Area Ranking Anti Infectives Azithral Anti-infective 32 21 4 2 Gastrology 6 Althrocin Anti-infective 92 28 Coug
Slide 11: Continued shift towards Specialty therapies
Continued shift towards Specialty therapies Therapy Dominance % of Domestic Formulations 44 40 51 47 58 54 56 60 49 53 42 46 FY11 FY12 FY13 FY14 FY15 YTD DEC FY16 Specialty Acute
Slide 12: Therapy-wise Performance Q3 FY16
Therapy-wise Performance Q3 FY16 DEC QTR 2015 DEC QTR 2014 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 14 2.05 29 34 13 1.80 33 31 Anti Diabetic 21 1.59 27 43
Slide 13: Fast emerging player in International Generics
Fast emerging player in International Generics International Generics Business - Key Highlights Own front-end marketing in the USA All Facilities approved for supply to regulated markets such as the US, Europe, Australia and Brazil Partnership with leading generic players in the US, Europe, Ca
Slide 14: Financial Snapshot
Financial Snapshot
Slide 15: Financial Highlights
Financial Highlights YTD DEC YTD DEC Particulars (INR mn) Q3 FY16 Q3 FY15 %Growth FY16 FY15 %Growth Formulations Revenue International 5211 1498 248% 12714 4351 192% India Branded 2883 2500 15% 8356 7488 12% India Generics 201 332 -40% 737 907 -19% API Revenue 1012 819 24% 3580 2852 26% Total Revenu
Slide 16: Financial Ratios
Financial Ratios Various Ratios YTD DEC FY 16 YTD DEC FY 15 FY 15 EBIDTA Margin 34.39% 19.66% 19.69% Gross Margin 74.35% 65.18% 65.29% ROCE 62.79% 31.32% 30.59% RONW 55.55% 32.00% 31.98% EPS 33.33 11.28 15.01 Book Value per share 79.75 46.87 46.93 Debt Equity Ratio 0.12 0.28 0.30 EBITDA / Debt Ratio
Slide 17: Revenue Trend
Revenue Trend CAGR 20677 18684 9808 8506 In INR mn 15260 7484 5819 5420 2358 3506 3389 3665 FY13 FY14 FY15 API International Formulations India Branded Formulations Total Revenue
Slide 18: Latest Shareholding Pattern
Latest Shareholding Pattern % of Total Shareholding 14 Promoter & Promoter group 12 FI/FII/MF 74 Public Market capitalization INR 131 bn Total paid-up share capital 377.03mn Total number of shares O/S 188.52mn No. of shareholders >50 K Free float market INR 34 bn capitalization
Slide 19: Strategy going forward
Strategy going forward Continue to focus on complex products. Expect to launch 7-9 products every year for the next three years in the US markets Aggressive investments in R&D and F&D activities to build robust pipeline of products for regulated markets More products through our USA front end.
Slide 20: Conference call details
Conference call details Date : Thursday, 21st January, 2016 Time : 05.00 pm IST India - Primary Number +91 22 39381028 India - Secondary Number +91 22 67468328 USA 1 866 746 2133 UK 0 808 101 1573 Singapore Toll Free No. 800 101 2045 Hong Kong Toll Free No. 800 964 448
Slide 21: About Alembic Pharmaceuticals Limited
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharm
Slide 22: Thank You
Thank You
Alembic Pharmaceuticals — Q3 FY16 Earnings Presentation on 6ix